Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

Objective: To identify predictive factors associated with operative morbidity, mortality, and
survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) …

Background The optimal preoperative treatment for locally advanced pancreatic cancer is
unknown. We aimed to compare the efficacy and safety of nab-paclitaxel plus gemcitabine …

Tumour-derived extracellular vesicles (EVs) are of increasing interest as a resource of
diagnostic biomarkers. However, most EV assays require large samples and are time …

Purpose: We hypothesized that autophagy inhibition would increase response to
chemotherapy in the preoperative setting for patients with pancreatic adenocarcinoma. We …

BACKGROUND: Experience with preoperative therapy for other cancers has led to an
assumption that borderline resectable pancreatic cancers can be converted to resectable …

Objective The survival benefit of adjuvant radiotherapy and 5-fluorouracil versus observation
alone after surgery was investigated in patients with pancreatic head and periampullary …

The efficacy of neoadjuvant therapy (NT) versus surgery first (SF) for pancreatic ductal
adenocarcinoma (PDAC) remains controversial. A random-effects meta-analysis of only …